Key statistics
As of last trade TAKEDAPH DRN (TAKP34:SAO) traded at 78.08, -7.60% below its 52-week high of 84.50, set on Aug 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 78.08 |
---|---|
High | 78.08 |
Low | 78.08 |
Bid | 76.32 |
Offer | 78.32 |
Previous close | 78.08 |
Average volume | 67.50 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Annual div (ADY) | 2.41 BRL |
---|---|
Annual div yield (ADY) | 3.30% |
Div ex-date | Mar 27 2024 |
Div pay-date | Jul 12 2024 |
Data delayed at least 15 minutes, as of Nov 22 2024 13:03 GMT.
More ▼
Press releases
- Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform
- Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
- Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
- Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
- Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
- Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
- Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
- Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
More ▼